One issue with early cancer screening blood tests in development is that the cancer site/organ of origin a priori is unknown. Quantigic® Genomics has developed a quant data analytics tool for identifying the cancer organ of origin/sub(type) via a novel technology which analyzes cancer genomic data using predictive proprietary tools from quantitative trading. To learn more, please email us: [email protected]. Quantigic® Genomics is a d/b/a name of Quantigic® Solutions, which has been providing innovative solutions and consulting services in quantitative analyses of business, financial and scientific data and information since 2008.